About Us
Atomo is an Australian headquartered medical device company supplying unique, integrated rapid diagnostic test devices to the global diagnostic market
Our Story
After ten years as a senior leader in the medical device sector, Atomo’s Founder and CEO John Kelly identified multiple ways in which diagnostics were ripe for transformation. John observed that usability, convenience, and simplicity of use could make a real difference in diagnostics. When people can’t use a product the way it is intended, the performance is undermined.
While John was exploring areas of the market where usability was poorly delivered, his youngest daughter was born and required intensive medical care for the first two years of her life. He watched as doctors struggled to collect blood from her arm. When John found out that the blood test they were doing only required a tiny drop of blood, he had a light bulb moment. John decided to develop a better, less invasive way to collect a blood sample.
The Opportunity
This is a pivotal moment in healthcare. Increased consumer acceptance of telemedicine and the need for faster information has generated even greater demand for rapid point of care diagnostics.
Since the COVID-19 pandemic, consumers, clinicians and regulators are more open to and supportive testing outside of clinical settings. Consumer rapid testing is now a standard ranged item in traditional pharmacy and retail channels, with increasing public health adoption of at-home and self-test technologies improving efficiencies and reducing perceived stigma associated with testing for certain infectious diseases
“These solutions reduce error rates, improve care and have significant commercial potential in both the developing world and in developed healthcare markets.”
– Dr. Curt LaBelle, Global Health Fund
Our Technology
Atomo has developed the most consumer friendly platform available for rapid at-home testing. Our integrated testing technology helps revolutionise access to healthcare solutions and deliver improved healthcare outcomes. We are a world leader in rapid testing solution that puts the user in the centre of the testing experience.
Independent studies have shown overwhelming user preference for Atomo's innovative and unique range of blood-based rapid diagnostic tests.
Our Products
Our finished rapid test products are marketed either under our own brand or through private labels via partners and regional distributors.
Our HIV Self Test is the world's first integrated, blood-based rapid diagnostic test (RDT) for HIV screening. It is globally recognised for its innovative design, high performance, and ease of use. With 99.6% specificity, 99.6% sensitivity, a requirement for only a small blood sample, and a 24-month shelf life, this test has the potential to save 40,000 lives annually in Africa alone.
Recognised Universally by Leading Global Regulatory Bodies
We have obtained regulatory approvals from the FDA in the US, the CE Mark in the EU/UK, the Australian TGA, and the World Health Organization.
